We also demonstrated that the effects of PPP inhibition on AKT activation and cell proliferation are PHLDA3-dependent and predict that the PHLDA3 status in human cancers may dictate their response to anti-PPP treatments. The gene discussed is PHLDA3; the disease is cancer.